
Sandoz is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz annually, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion. Read our community engagement guidelines: http://bit.ly/4ofoggc
解鎖市場時間軸與訊號動態
過去 90 日內有 150 個訊號。
此公司進入各市場的次序 — 由最舊至最新
10 active postings
54 active postings
註冊以查看完整訊號動態
Sandoz 的國際擴張與競爭對手的比較
長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
Sandoz你 | 25 | 1 | +245% | 138 | 32 |
Launch Manager
查看招聘Kyiv, Kyiv City, Ukraine · 今日
Medical Representative (Ha Noi)
查看招聘Vietnam · 昨日
Медицинский представитель (Pharmacy Line), г. Ярославль
查看招聘Yaroslavl, Yaroslavl’, Russia · Full-time · 昨日
Personal growth & learning at Sandoz
已結束Antimicrobial resistance is reducing the effectiveness of antibiotics – medicines that underpin our modern healthcare system. Without antibiotics, routine infections become harder to treat and complex procedures carry greater risk. In the United States, more than 2.8 million antimicrobial resistant infections occur each year, according to the CDC. This is not a future threat. It is already here.As an industry, we all have a role to play to ensure reliable access to high quality antibiotics, buil ...
已結束Join us!
進行中復宏漢霖2025上半年營收增長2.7%,毛利潤增長10.5%,經營性現金流增長206.8%。海外產品利潤激增超200%。
復宏漢霖2025年上半年收入增長2.7%,毛利潤增長10.5%,經營現金流增長206.8%。海外產品利潤激增超200%。
山德士在德國推出10、15和20毫克劑量的利伐沙班仿製藥,為患者提供高質量、價格實惠的替代選擇,具有目錄價格優勢。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Sandoz 業務、市場及增長訊號的快速解答。
